Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension
Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension
复制标题
DOI：
10.1161/01.hyp.0000179582.42830.1d
复制
发表时间：
2005-09-01
期刊：
影响因子：
8.3
通讯作者：
Pratt, JH
中科院分区：
文献类型：
--
作者：
Saha, C;Eckert, GJ;Pratt, JH
Hypertension in blacks is more prevalent and less often controlled than the hypertension of other ethnic groups. We sought to explore the benefit of adding inhibitors of the epithelial sodium channel ( ENaC), an aldosterone- regulated site of sodium reabsorption in the distal nephron, to the antihypertensive regimen of black hypertensive patients. In a prospective, randomized, placebo- controlled, double- blind clinical trial, we used a 2- by- 2 factorial design with 4 treatment groups: amiloride ( a direct inhibitor of ENaC), spironolactone ( an aldosterone receptor antagonist), the combination of both drugs, and placebo. The subjects ( n = 98) had an elevated blood pressure despite treatment that included a diuretic and a calcium channel blocker; the level of plasma renin activity was
